Drug Profile
MK 0952
Alternative Names: MK-0952Latest Information Update: 16 Sep 2008
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antidementias
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 16 Sep 2008 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
- 16 Sep 2008 Discontinued - Phase-II for Alzheimer's disease in United Kingdom (PO)
- 15 Dec 2005 Phase-I clinical trials in Alzheimer's disease in USA (unspecified route)